EYED PHARMA
ActiveSummary
EYED PHARMA has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €17.37M and a net result of €-6.92M. Equity is growing by ~18.7% per year across the filed fiscal years. Its solvency ranks better than 54% of 244 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Credit check for your own amount and term
Signals
Checked, nothing found (2)
Financials · fiscal year 2025, full schema
Filed annual accounts As filed with the NBB · 2025 against 2024 · 54 lines
The notes to these accounts (19 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Turnover70 | - | - | - | €11.76M | €10.49M | ▼ 10.8% |
| Goods, raw materials, services and sundry goods60/61 | - | - | - | €11.51M | €9.96M | ▼ 13.4% |
| Remuneration, social security and pensions62 | €2.96M | €4.12M | €4.54M | €4.06M | €3.15M | ▼ 22.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €2.00M | €2.80M | €4.19M | €4.41M | €5.47M | ▲ 24.1% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | €0 | €2k | - | - | - | - |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | €-62k | - | - | - |
| Other operating charges640/8 | €70k | €20k | €192k | €95k | €76k | ▼ 20.6% |
| Non-recurring operating charges66A | €1.38M | €1.51M | - | - | - | - |
| Gross operating margin9900 | €1.28M | €1.09M | €1.10M | €254k | €531k | ▲ 109% |
| Operating profit (loss)9901 | €-5.13M | €-7.36M | €-7.76M | €-8.31M | €-8.17M | ▲ 1.7% |
| Financial income75/76B | €404k | €964k | €1.60M | €1.40M | €2.31M | ▲ 64.9% |
| Recurring financial income75 | €404k | €797k | €1.60M | €1.40M | €2.30M | ▲ 64.1% |
| Non-recurring financial income76B | - | €168k | - | - | €10k | - |
| Financial charges65/66B | €271k | €247k | €200k | €356k | €1.31M | ▲ 267% |
| Recurring financial charges65 | €271k | €247k | €200k | €356k | €1.31M | ▲ 267% |
| Profit (loss) for the period before taxes9903 | €-5.00M | €-6.65M | €-6.35M | €-7.27M | €-7.17M | ▲ 1.4% |
| Income taxes67/77 | €-312k | €-335k | €-317k | €-325k | €-246k | ▲ 24.3% |
| Profit (loss) for the period9904 | €-4.69M | €-6.31M | €-6.03M | €-6.94M | €-6.92M | ▲ 0.3% |
| Profit (loss) for the period to be appropriated9905 | €-4.69M | €-6.31M | €-6.03M | €-6.94M | €-6.92M | ▲ 0.3% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €32.75M | €27.11M | €37.87M | €42.33M | €50.61M | ▲ 19.6% |
| Formation expenses20 | €2k | €1k | €306 | - | - | - |
| Fixed assets21/28 | €12.90M | €18.93M | €23.80M | €29.08M | €32.50M | ▲ 11.8% |
| Intangible fixed assets21 | €12.32M | €18.37M | €23.46M | €28.75M | €32.15M | ▲ 11.8% |
| Tangible fixed assets22/27 | €509k | €479k | €310k | €310k | €342k | ▲ 10.6% |
| Plant, machinery and equipment23 | €390k | €367k | €256k | €281k | €320k | ▲ 13.6% |
| Furniture and vehicles24 | €119k | €106k | €54k | €28k | €23k | ▼ 19.5% |
| Assets under construction and advance payments27 | - | €5k | - | - | - | - |
| Financial fixed assets28 | €72k | €74k | €34k | €15k | €12k | ▼ 19.9% |
| Current assets29/58 | €19.84M | €8.18M | €14.07M | €13.26M | €18.11M | ▲ 36.6% |
| Amounts receivable after more than one year29 | - | - | €1.07M | €1.39M | €1.61M | ▲ 16.0% |
| Other amounts receivable291 | - | - | €1.07M | €1.39M | €1.61M | ▲ 16.0% |
| Stocks and contracts in progress3 | €544k | €455k | €597k | - | - | - |
| Stocks30/36 | €544k | €455k | €597k | - | - | - |
| Amounts receivable within one year40/41 | €4.59M | €2.50M | €10.88M | €8.62M | €13.43M | ▲ 55.8% |
| Trade receivables40 | €1.28M | €1.54M | €1.37M | €299k | €315k | ▲ 5.1% |
| Other amounts receivable41 | €3.31M | €959k | €9.51M | €8.32M | €13.12M | ▲ 57.7% |
| Cash at bank and in hand54/58 | €13.50M | €3.47M | €1.03M | €1.21M | €1.30M | ▲ 7.1% |
| Deferred charges and accrued income490/1 | €1.21M | €1.75M | €489k | €2.03M | €1.76M | ▼ 13.2% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €32.75M | €27.11M | €37.87M | €42.33M | €50.61M | ▲ 19.6% |
| Equity10/15 | €20.25M | €16.30M | €27.52M | €22.78M | €17.37M | ▼ 23.8% |
| Contributions10/11 | €27.91M | €27.91M | €24.85M | €24.85M | €24.85M | = |
| Capital10 | €27.91M | €27.91M | €24.85M | €24.85M | €24.85M | = |
| Issued capital100 | €27.91M | €27.91M | €24.85M | €24.85M | €24.85M | = |
| Profit (loss) carried forward14 | €-12.72M | €-19.03M | €-6.03M | €-12.98M | €-19.90M | ▼ 53.3% |
| Investment grants15 | €5.06M | €7.42M | €8.71M | €10.91M | €12.42M | ▲ 13.8% |
| Amounts payable17/49 | €12.50M | €10.81M | €10.34M | €19.55M | €33.24M | ▲ 70.0% |
| Amounts payable after more than one year17 | €5.92M | €2.23M | €4.55M | €10.35M | €24.92M | ▲ 141% |
| Financial debts170/4 | €5.92M | €2.23M | €4.55M | €10.35M | €24.92M | ▲ 141% |
| Amounts payable within one year42/48 | €6.54M | €8.54M | €5.78M | €9.19M | €8.15M | ▼ 11.3% |
| Current portion of amounts payable after more than one year42 | €858k | €1.49M | €1.33M | €620k | €996k | ▲ 60.8% |
| Financial debts43 | €3.50M | €1.94M | - | €5.50M | €5.50M | = |
| Credit institutions430/8 | €3.50M | €1.00M | - | €5.50M | €5.50M | = |
| Other loans439 | - | €935k | - | - | - | - |
| Trade debts44 | €1.83M | €2.06M | €3.77M | €2.42M | €1.31M | ▼ 45.8% |
| Suppliers440/4 | €1.83M | €2.06M | €3.77M | €2.42M | €1.31M | ▼ 45.8% |
| Taxes, remuneration and social security45 | €311k | €754k | €676k | €656k | €347k | ▼ 47.0% |
| Taxes450/3 | €846 | - | - | - | - | - |
| Remuneration and social security454/9 | €310k | €754k | €676k | €656k | €347k | ▼ 47.0% |
| Other amounts payable47/48 | €41k | €2.30M | - | €528 | - | - |
| Accrued charges and deferred income492/3 | €41k | €40k | €12k | €9k | €171k | ▲ 1,870% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €-4.69M | €-6.31M | €-6.03M | €-6.94M | €-6.92M | ▲ 0.3% |
| + Depreciation and write-downs630 | €2.00M | €2.80M | €4.19M | €4.41M | €5.47M | ▲ 24.1% |
| Operating cash flow (approximation) | €-2.68M | €-3.51M | €-1.85M | €-2.53M | €-1.45M | ▲ 42.7% |
| Investment in fixed assets (approximation) | - | €-8.83M | €-9.06M | €-9.69M | €-8.90M | ▲ 8.2% |
| Change in cash | - | €-10.03M | €-2.44M | €181k | €86k | ▼ 52.1% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
18-11
State Gazette act
Appointments: Mélanie MESTDAGT, Pierre BELICHARD and 2 othersResignations: SRL OUKELOS, SA QBIC VENTURE PARTNERS II and Carolyn MYERS · Reappointments: Marc FOIDART, Jean-Marie RAKIC and NOSHAQ SA · Permanent representatives: François MEURGEY, Sofie BAETEN and Eric BRANDT15 facts ▸
- Board meeting, 20-02-2024
- Director appointment, Mélanie MESTDAGT (ceo déléguée à la gestion journalière)
- General meeting, 03-07-2025
- Director resignation, SRL OUKELOS (independent director)
- Director resignation, SA QBIC VENTURE PARTNERS II (administrateur de classe c)
- Director appointment, Pierre BELICHARD (independent director)
- Director appointment, Robert TAUB (administrateur de classe c)
- Director resignation, Carolyn MYERS (independent director)
- Director appointment, Jean-Philippe COMBAL (independent director)
- Director reappointment, Marc FOIDART (administrateur de classe a)
- Director reappointment, Jean-Marie RAKIC (administrateur de classe a)
- Director reappointment, NOSHAQ SA (administrateur de classe b)
- +3 further facts in this act
23-11
State Gazette act
Resignations: REWISE AD REVISEUR D'ENTREPRISES SRL (statutory auditor) and Lawrence VAN HELLEPUTTE (director)Appointment: BDO EXPERTS COMPTABLES & CONSEILLERS FISCAUX (statutory auditor) · Permanent representative: Bert DE LEEUW · Capital decrease10 facts ▸
- General meeting, 20-11-2023
- Capital decrease, €19.033.744
- Capital, €24.847.913,5
- Statutes amendment
- Auditor resignation, REWISE AD REVISEUR D'ENTREPRISES SRL
- Auditor appointment, BDO EXPERTS COMPTABLES & CONSEILLERS FISCAUX (statutory auditor)
- Director resignation, Lawrence VAN HELLEPUTTE
- Permanent representative, Bert DE LEEUW
- Power of attorney, Manon DEPREZ
- Power of attorney, Marc FOIDART
04-04
State Gazette act
Permanent representative: Sofie Baeten1 fact ▸
- Permanent representative, Sofie Baeten
24-01
State Gazette act
Resignation: PIENTER-JAN (administrateur de classe c)Appointment: FUND+ (administrateur de classe c) · Permanent representative: Lawrence VAN HELLEPUTTE · Capital increase14 facts ▸
- General meeting, 20-01-2023
- Capital increase, €15.970.358
- Bank account, BE42 0882 8499 1954
- Capital, €43.881.657,5
- Share issue, Droits de souscription anti-dilutifs, 110
- Share issue, Droits de souscription ESOP 2022, 177500
- Share issue, Droits de souscription ESOP 2023, 177500
- Statutes amendment
- Director resignation, PIENTER-JAN (administrateur de classe c)
- Director discharge, PIENTER-JAN
- Director appointment, FUND+ (administrateur de classe c)
- Permanent representative, Lawrence VAN HELLEPUTTE
- +2 further facts in this act
Show earlier events
23-05
State Gazette act
Registered officeRegistered-office move2 facts ▸
- Board meeting, 24-03-2022
- Registered-office move, rue Louis Plescia, 9 à 4102 Seraing (Ougrée)
27-12
State Gazette act
Capital & shares · Statutes amendment · Resignations & appointmentsCapital increase · Share issue · Capital6 facts ▸
- General meeting, 20-12-2021
- Capital increase, €15.970.358
- Share issue, Droits de souscription anti-dilutifs, 115
- Share issue, Droits de souscription indemnitaires, 230
- Capital, €27.911.299,5
- Statutes amendment
30-04
State Gazette act
Capital & shares · Statutes amendmentCapital increase · Share issue · Capital7 facts ▸
- Board meeting, 06-04-2021
- Capital increase, €100.000
- Share issue, A, 100000
- Capital, €11.940.941,5
- Statutes amendment
- Power of attorney, Anne MICHEL
- Power of attorney, MESTDAGT Mélanie
25-11
State Gazette act
Permanent representatives: Jean Emile Léon Joseph VAN NUWENBORG and Éric BRANDTCapital increase · Bank account · Capital11 facts ▸
- General meeting, 30-09-2019
- Capital increase, €3.904.732,73
- Bank account, BE42 0882 8499 1954
- Capital, €11.840.941,5
- Share issue, Droits de souscription anti-dilutifs, C
- Share issue, Droits de souscription ESOP 2019, A
- Permanent representative, Jean Emile Léon Joseph VAN NUWENBORG
- Permanent representative, Éric BRANDT
- Statutes amendment
- Power of attorney, Mélanie MESTDAGT
- Subscription rights annulment, Droits de souscription anti-dilutifs, 80
25-11
State Gazette act
Capital & shares · RestructuringDemerger · Accounting effect · Share issue8 facts ▸
- General meeting, 30-10-2019
- Demerger, scission partielle par constitution de nouvelle société, ensemble des éléments relatifs à la production d'implants oculaires
- Accounting effect, 01-07-2019
- Share issue, 1904688, rémunération de l'apport en nature
- Capital decrease, €1.306.541,23
- Capital, €7.936.208,77
- Statutes amendment
- Power of attorney, Mélanie MESTDAGT
12-09
State Gazette act
RestructuringAppointment: REWISE AD REVISEUR D'ENTREPRISES SOPRL (réviseur d'entreprises) · Demerger · Capital8 facts ▸
- Board meeting, 30-08-2019
- Demerger, transfert de l'ensemble des éléments relatifs à la production d'implants oculaires
- Capital, €9.242.750
- Net-asset statement, 30-06-2019
- Capital, €1.306.541,23
- Accounting effect, 01-07-2019
- Auditor appointment, REWISE AD REVISEUR D'ENTREPRISES SOPRL (réviseur d'entreprises)
- Power of attorney, Raphaël DOUNY
13-06
State Gazette act
Resignation: EyeD PHARMA (director)Appointments: OUKELOS, Marc FOIDART and 5 others · Permanent representatives: François MEURGEY, Chris BUYSE and 2 others · Capital increase21 facts ▸
- General meeting, 09-05-2019
- Capital increase, €4.107.750
- Share issue, warrants anti-dilutifs, 80
- Statutes amendment
- Statutes amendment
- Capital, €9.242.750
- Director resignation, EyeD PHARMA
- Director discharge, EyeD PHARMA
- Director appointment, OUKELOS (independent director)
- Permanent representative, François MEURGEY
- Director appointment, Marc FOIDART (class A director)
- Director appointment, Denis KNOOPS (independent director)
- +9 further facts in this act
10-07
State Gazette act
Appointment: Denis KNOOPS (director)Capital increase · Bank account · Capital7 facts ▸
- General meeting, 03-07-2018
- Capital increase, €2.567.500
- Bank account, BE42 0882 8499 1954
- Capital, €5.135.000
- Statutes amendment
- Director appointment, Denis KNOOPS (director)
- Power of attorney, Mélanie MESTDAGT
13-12
State Gazette act
Appointments: Société d'Investissement et de Participation du Bassin de Liège, Henri Lemaître and 3 othersPermanent representatives: Françoise Leblanc and Marc Foidart · Reappointments: Marc Foidart, Biofinance Consulting and Jean-Marie Rakic · Resignations: OUSIA (director) and Christine Jérôme (director)13 facts ▸
- General meeting, 30-06-2016
- Director appointment, Société d'Investissement et de Participation du Bassin de Liège (director)
- Permanent representative, Françoise Leblanc
- Director appointment, Henri Lemaître (director)
- Director appointment, Jean-Michel Foidart (director)
- Director appointment, Mercury Leadership and Management (director)
- Director reappointment, Marc Foidart (director)
- Director reappointment, Biofinance Consulting (managing director)
- Director reappointment, Jean-Marie Rakic (président du conseil d'adm.)
- Director resignation, OUSIA (director)
- Permanent representative, Marc Foidart
- Director resignation, Christine Jérôme (director)
- +1 further facts in this act
08-07
State Gazette act
Capital & shares · Statutes amendmentCapital increase · Bank account · Capital8 facts ▸
- General meeting, 22-06-2016
- Capital increase, €1.967.500
- Bank account, BE89 0882 7497 4985
- Capital, €2.567.500
- Statutes amendment
- Power of attorney, Mélanie MESTDAGT
- Share categories, 893500, 100000
- Power of attorney, Françoise LEBLANC
06-05
State Gazette act
Capital & sharesShare issue · Power of attorney · Warrant exercise period6 facts ▸
- General meeting, 14-04-2016
- Share issue, 100000, warrants
- Power of attorney, Mélanie MESTDAGT
- Warrant exercise period, 14-04-2021, 01-01-2020
- Warrant transferability, registre de Détenteurs de Warrants au siège social
- Share form, nominative
02-05
State Gazette act
Appointment: Marc Foidart (director)Resignation: Majocepi (director)3 facts ▸
- General meeting, 01-02-2016
- Director appointment, Marc Foidart (director)
- Director resignation, Majocepi (director)
18-05
State Gazette act
Registered officeRegistered-office move2 facts ▸
- General meeting, 06-05-2015
- Registered-office move, Quartier Hôpital, Avenue Hippocrate 5, 4000 Liège
19-12
State Gazette act
Appointments: Jean-Marie RAKIC, BIOFINANCE CONSULTING and 3 othersPermanent representatives: Mélanie MESTDAGT, Jean-Michel FOIDART and Marc FOIDART · Capital increase · Bank account16 facts ▸
- General meeting, 30-10-2013
- Capital increase, €580.000
- Bank account, Banque AXA, BE12 7512 0617 8792
- Legal-form conversion, Société Anonyme
- Net-asset statement, 30-09-2013
- Capital, €600.000
- Director appointment, Jean-Marie RAKIC (chair)
- Director appointment, BIOFINANCE CONSULTING (managing director)
- Permanent representative, Mélanie MESTDAGT
- Director appointment, MAJOCEPI (director)
- Permanent representative, Jean-Michel FOIDART
- Director appointment, OUSIA (director)
- +4 further facts in this act
24-12
State Gazette act
IncorporationAppointment: RAKIC Jean-Marie Ante (non-statutory manager) · Founding capital · Power of attorney7 facts ▸
- Incorporation, 14-12-2012
- Founding capital, €20.000
- Director appointment, RAKIC Jean-Marie Ante (non-statutory manager)
- Power of attorney, RAKIC Jean-Marie Ante
- Power of attorney, RAKIC Jean-Marie Ante
- Power of attorney, RAKIC Jean-Marie Ante
- Assumption of prior commitments, Le gérant reprend les engagements, ainsi que les obligations qui en résultent, et toutes les activités entreprises depuis le 1er février 2012 par ses soins au n…
About the unread acts
Of the 20 Belgian State Gazette acts we know for this company, 19 have been read. The other one has not been read yet: what they contain is neither established nor disproved here.
Directors · office · real estate
12 other directors
Not every act has been read: a resignation may be missing here
1 establishment unit
1 parcel
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62343C0011/00N005 | Wallonia | 8,627 m² | - | - |
Linked by address, not proof of ownership
Statutory auditor
1 auditor| BDO EXPERTS COMPTABLES & CONSEILLERS FISCAUXCurrent Statutory auditor · represented by Cédric ANTONELLI | 20-11-2023 → present |
Show 1 earlier auditors
| REWISE AD REVISEUR D'ENTREPRISES SOPRL Réviseur d'entreprises succeeded by BDO EXPERTS COMPTABLES & CONSEILLERS FISCAUX in 2023 | 02-09-2019 → 20-11-2023 |
Articles of association
Full purpose
Le développement, la production et la commercialisation de médicaments sous les formes les plus diverses, d'implants médicaux à visée thérapeutique, de formulations galéniques, et notamment dans le domaine ophtalmologique ; L'achat, la détention, la vente, la cession, l'échange, la gestion de toute valeur mobilière, action, obligation ou titre de prêt émis par toutes sociétés belge ou étrangère, part sociale ou autres droits sociétaires ; La prise de participation sous quelque forme que ce soit dans des sociétés industrielles, commerciales, financières, existantes ou à constituer ; La réalisation de toutes opérations financières à l'exception de celles réservées par la loi aux banques et caisses d'épargne et de celles visées par l'arrêté royal du cinq août 1991 relatif à la gestion de fortune et au conseil de placements. La réalisation de toute opération à caractère immobilier, telle que l'achat, la détention, la vente, la cession, l'échange, la construction, la gestion de toutes propriétés immobilières, bâties ou non bâties, qu'elle peut également donner en location en ce compris la location-financement ; L'exercice et l'application de tous droits et pouvoirs conférés par ou attachés à la propriété de toute action, valeur mobilière ou autres titres comprenant et ceci sans préjudice de ce qui précède, tous pouvoirs de veto ou de contrôle conféré en vertu de la participation par la société d'une partie ou d'une quotité spéciale du capital souscrit et pourvoir des services de management et autres services de direction, de supervision ou de conseil pour ou en relation avec toute société dans laquelle la société est intéressée, aux conditions qu'elle jugera bonnes ; L'exercice des fonctions de mandataire sous toutes formes, de gérant, d'administrateur et/ou de liquidateur dans d'autres sociétés, participées ou non, en Belgique et à l'étranger ; La réalisation de toutes prestations de conseil, d'expertise et de formation pour toutes entreprises et sociétés de services notamment dans les domaines de l'administration, marketing, du management, de la stratégie d'entreprise, de la finance, des mathématiques, de l'informatique et de l'économie, ce dans le sens le plus large du terme ; Le développement, l'achat, la vente, la gestion, la mise en valeur, la prise ou l'attribution de licences, de brevets, de know-how, et autres droits intellectuels ; La gestion, dans la plus large acception du terme, de son patrimoine immobilier propre.
Structure & network
Connections & network
22 connected companiesShow 18 more companies with a shared director
Acquisitions and mergers
1 transactionCapital and shareholders
- NOEL Agnès
- JEROME Christine
- VAN CAUWENBERGE Françoise
- MESTDAGT Mélanie
- Jean-Marie RAKIC
- OUSIA
- Marc FOIDART
- Céline FOIDART
- OPHTALMOS
- MEUSINVEST
- Henri LEMAÎTRE
- André MALHERBE
- Fabienne WIJZEN
- Denis KNOOPS
- FUND+ (BE 0629.896.521)
- QBIC II FUND ARKIV (BE 0066.851.707)
- FIDOUNA (BE 0543.570.380)
- GOSA (BE 0714.928.503)
- INVEST4EYED
- SPINVENTURE (BE 0465.001.172)
- Jean-Marie RAKIC 42,494 shares · 254,966.35 EUR
- Yvette POUTCHINIAN 3,333 shares · 20,000 EUR
- Agnès NOEL 3,993 shares · 23,956 EUR
- OUSIA 8,603 shares · 51,618.14 EUR
- Marc FOIDART 62,473 shares · 374,835.86 EUR
- John FOIDART 24,654 shares · 147,923 EUR
- Pierre FOIDART 24,654 shares · 147,923 EUR
- Céline FOIDART 24,654 shares · 147,923 EUR
- OPHTALMOS 81,144 shares · 486,866.17 EUR
- MEUSINVEST 83,333 shares · 499,998 EUR
- Henri LEMAÎTRE 17,956 shares · 107,735.29 EUR
- André MALHERBE 17,956 shares · 107,735.29 EUR
- Fabienne WIJZEN 2,868 shares · 17,208.48 EUR
- Mélanie MESTDAGT 2,868 shares · 17,208.48 EUR
- Philippe Jean-Marie Léopold DEGEER 26,934 shares · 161,602.94 EUR
- SOCIETE D'INVESTISSEMENT ET DE PARTICIPATION DU BASSIN DE LIEGE (BE 0426.624.509) 100,000 shares · 500,000 EUR
- OPHTALMOLOGIE CHIRURGICALE VAN CAUWENBERGE RAKIC (BE 0831.531.510) 4,000 shares · 20,000 EUR
- André MALHERBE 20,000 shares · 100,000 EUR
- Henri LEMAÎTRE 20,000 shares · 100,000 EUR
- Yvette POUTCHINIAN 5,000 shares · 25,000 EUR
- John FOIDART 20,000 shares · 100,000 EUR
- Pierre FOIDART 20,000 shares · 100,000 EUR
- Céline FOIDART 20,000 shares · 100,000 EUR
- Marc FOIDART 60,000 shares · 300,000 EUR
- OPHTALMOS (BE 0656.813.922) 94,500 shares · 472,500 EUR
- MERCURY LEADERSHIP AND MANAGEMENT (BE 0640.709.051) 30,000 shares · 150,000 EUR
- RAKIC Jean-Marie 64,438 EUR
- POUTCHINIAN Yvette 96,657 EUR
- DUCHATEAU Edouard 64,438 EUR
- NOEL Agnès 32,219 EUR
- MAJOCEPI SPRL 257,810 EUR
- Ousia SPRL 64,438 EUR
The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.
- 23-11-2023 Capital reduction of 19,033,744 EUR · to 24,847,913.50 EUR · to absorb losses
- 24-01-2023 Capital increase of 15,970,358 EUR · to 43,881,657.50 EUR · 1,581,046 new shares
- 27-12-2021 Capital increase of 15,970,358 EUR · to 27,911,299.50 EUR · 1,581,046 new shares
- 30-04-2021 Capital increase of 100,000 EUR · to 11,940,941.50 EUR
- 25-11-2019 Capital reduction of 1,306,541.23 EUR · to 7,936,208.77 EUR
- 25-11-2019 Capital increase of 3,904,732.73 EUR · to 11,840,941.50 EUR · 483,259 new shares
- 12-09-2019 Capital stated in the act · 9,242,750 EUR · 1,904,688 shares
- 13-06-2019 Capital increase of 4,107,750 EUR · to 9,242,750 EUR · 483,271 new shares
Show 4 older capital entries
- 10-07-2018 Capital increase of 2,567,500 EUR · to 5,135,000 EUR · 427,917 new shares
- 08-07-2016 Capital increase of 1,967,500 EUR · to 2,567,500 EUR · 393,500 new shares
- 19-12-2013 Capital increase of 580,000 EUR · to 600,000 EUR
- 24-12-2012 Incorporation · 20,000 EUR · 20,000 shares
Similar companies · same sector, comparable size
Identification & contact
Scores and ratios are computed by Checked and are not a credit decision.